Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study

Publisher： John Wiley & Sons Inc

E-ISSN： 1531-8257|30|7|912-918

ISSN： 0885-3185

Source： MOVEMENT DISORDERS, Vol.30, Iss.7, 2015-06, pp. : 912-918

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 7, 2015-06 ,pp. : 1009-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

The treatment of mild cognitive impairment associated with Parkinson's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 7, 2015-06 ,pp. : 881-882

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study

By  

ACTA NEUROLOGICA SCANDINAVICA (ELECTRONIC), Vol. 131, Iss. 5, 2015-05 ,pp. : 275-281

John Wiley & Sons Inc

Access to resources Recommend Favorite

Parkinson's disease‐cognitive rating scale: Psychometrics for mild cognitive impairment

By  

MOVEMENT DISORDERS, Vol. 28, Iss. 10, 2013-09 ,pp. : 1376-1383

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration

By  

MOVEMENT DISORDERS, Vol. 28, Iss. 10, 2013-09 ,pp. : 1360-1369

John Wiley & Sons Inc

Access to resources Recommend Favorite